Blog

Latest news about encapsia

Encapsia expands its global reach and service offering

We are excited to announce that Cmed has today joined the AIXIAL Group and ALTEN Group.

ALTEN is a world leader in Engineering and Technology consulting with 37,000 engineers and scientists located in more than 30 countries throughout the world. It serves customers in a range of industries and has a depth and breadth of experience and expertise across life sciences, software development and artificial intelligence.

AIXIAL Group, an ALTEN company, is a CRO renowned for its flexible and functional resourcing. Through this acquisition, the AIXIAL Group continues to build its global presence with over 1,000 employees. Cmed’s experience, expertise and technology approach perfectly align with the AIXIAL Group’s vision to provide expert services to clients and transform the clinical trials landscape for the benefit of patients.

Cmed Technology is now able to offer an even greater breadth and capability to improve client trial operations through the substantial expertise, capabilities and scale of ALTEN and AIXIAL.

A copy of the recent press releases from ALTEN, Cmed and Aixial are available at this link for your information.

Encapsia expands its global reach and service offering

Latest articles

Innovative technology for clinical trials is now, more than ever, necessary to deliver decentralized trials (DCT) and enable design of hybrid protocols that support trial continuity and patient-centricity. We’ve added new capabilities for encapsia, after we’ve seen increased demand for its use in decentralized trials. Encapsia delivers a complete solution to gather and manage multiple live clinical data sources and apply real-time data management, sophisticated visualizations, analytics, and AI. Encapsia was designed to address the pain around remote collection, integration, and availability of disparate data.
Decentralized trials are defined by the FDA as the decentralization of clinical trial operations where technology is used to communicate with study participants and collect data. These trials can be fully DCT (the study participant can participate in the entire clinical trial from their home or other convenient location) or hybrid DCT (combine the use of both sites and remote locations and is currently the most common type of DCT being implemented).
We are excited to announce that Cmed has today joined the AIXIAL Group and ALTEN Group. ALTEN is a world leader in Engineering and Technology consulting with 37,000 engineers and scientists located in more than 30 countries throughout the world. It serves customers in a range of industries and has a depth and breadth of experience and expertise across life sciences, software development and artificial intelligence. AIXIAL Group, an ALTEN company, is a CRO renowned for its flexible and functional resourcing.